Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Fate Therapeutics, Inc. (FATE : NSDQ)
 
 • Company Description   
Fate Therapeutics is a clinical-stage biopharmaceutical company, which is focused on the development of programmed cellular immunotherapies for cancer and immune disorders.? The company uses various therapeutic approaches for cell programming to develop cell therapies. The company programs cells of the blood and immune system, including natural killer (NK) cells, T cells and CD34 cells, and is advancing a pipeline of programmed cellular immunotherapies. It uses pharmacologic modulators, such as small molecules, to enhance the biological properties and therapeutic function of healthy donor-sourced cells ex vivo before the product candidates are administered to a patient. It also uses human induced pluripotent stem cells (iPSCs) to generate a clonal master iPSC line having preferred biological properties and direct the fate of the clonal master iPSC line to create its cell therapy product candidate.

Number of Employees: 449

 
 • Price / Volume Information   
Yesterday's Closing Price: $23.10 Daily Weekly Monthly
20 Day Moving Average: 1,727,012 shares
Shares Outstanding: 96.63 (millions)
Market Capitalization: $2,232.13 (millions)
Beta: 1.69
52 Week High: $97.43
52 Week Low: $20.49
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -33.08% -24.64%
12 Week -31.96% -25.20%
Year To Date -60.52% -53.22%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
12278 SCRIPPS SUMMIT DRIVE
-
SAN DIEGO,CA 92131
USA
ph: 858-875-1800
fax: -
christina@sternir.com http://www.fatetherapeutics.com
 
 • General Corporate Information   
Officers
J. Scott Wolchko - Chief Executive Officer and President
William H. Rastetter - Chairman of the Board and Director
John D. Mendlein - Vice Chairman of the Board and Director
Edward J. Dulac III - Chief Financial Officer
Shefali Agarwal - Director

Peer Information
Fate Therapeutics, Inc. (CORR.)
Fate Therapeutics, Inc. (RSPI)
Fate Therapeutics, Inc. (CGXP)
Fate Therapeutics, Inc. (BGEN)
Fate Therapeutics, Inc. (GTBP)
Fate Therapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 31189P102
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/03/22
Share - Related Items
Shares Outstanding: 96.63
Most Recent Split Date: (:1)
Beta: 1.69
Market Capitalization: $2,232.13 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.86 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-3.37 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 13.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/03/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 3.52
Price/Cash Flow: -
Price / Sales: 35.36
EPS Growth
vs. Year Ago Period: -41.67%
vs. Previous Quarter: 5.56%
Sales Growth
vs. Year Ago Period: 65.27%
vs. Previous Quarter: 7.89%
ROE
03/31/22 - -34.89
12/31/21 - -30.25
09/30/21 - -28.25
ROA
03/31/22 - -25.80
12/31/21 - -22.50
09/30/21 - -20.45
Current Ratio
03/31/22 - 7.69
12/31/21 - 7.79
09/30/21 - 7.55
Quick Ratio
03/31/22 - 7.69
12/31/21 - 7.79
09/30/21 - 7.55
Operating Margin
03/31/22 - -386.23
12/31/21 - -399.63
09/30/21 - -343.14
Net Margin
03/31/22 - -368.76
12/31/21 - -379.89
09/30/21 - -359.66
Pre-Tax Margin
03/31/22 - -368.76
12/31/21 - -379.89
09/30/21 - -359.65
Book Value
03/31/22 - 6.55
12/31/21 - 7.11
09/30/21 - 7.67
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©